Plain-English translation of NCT06896916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called given as an intravenous infusion combined with an oral medication called . The study is for people with relapsed or refractory multiple myeloma — a blood cancer that has either come back or stopped responding to previous treatments. Researchers want to find the right dose of this medication combination and see how well it works.
Multiple myeloma patients whose cancer stops responding to standard treatments have very few options left. This trial is exploring whether this new medication combination might help people in this difficult situation by targeting cancer cells in a different way.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication at a treatment center, combined with oral pills you take at home. The study lasts approximately 10.75 years, though not every visit requires the same commitment. The trial is divided into two phases: the first phase finds the right dose for everyone, and the second phase tests that dose in a larger group of participants to confirm it works and is safe.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States